​
​

Day One Biopharmaceuticals (DAWN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DAWN Stock Forecast

Day One Biopharmaceuticals stock forecast is as follows: an average price target of $38.80 (represents a 182.80% upside from DAWN’s last price of $13.72) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

DAWN Price Target

The average price target for Day One Biopharmaceuticals (DAWN) is $38.80 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $24.00. This represents a potential 182.80% upside from DAWN's last price of $13.72.

DAWN Analyst Ratings

Buy

According to 5 Wall Street analysts, Day One Biopharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for DAWN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Day One Biopharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 01, 2024Alec StranahanBank of America Securities--67.71%74.93%
May 07, 2024Andrew MaldonadoH.C. Wainwright--140.96%191.55%
Jan 08, 2023Joseph CatanzaroPiper Sandler--110.87%227.99%
Dec 15, 2022H.C. Wainwright--61.96%155.10%
Dec 14, 2022Needham--94.84%191.55%
Dec 05, 2022Goldman Sachs--106.99%227.99%
Jun 20, 2022Joseph CatanzaroPiper Sandler--153.32%191.55%
Row per page
Go to

The latest Day One Biopharmaceuticals stock forecast, released on Aug 01, 2024 by Alec Stranahan from Bank of America Securities, set a price target of $24.00, which represents a 67.71% increase from the stock price at the time of the forecast ($14.31), and a 74.93% increase from DAWN last price ($13.72).

Day One Biopharmaceuticals Price Target by Period

1M3M12M
# Anlaysts--2
Avg Price Target--$32.00
Last Closing Price$13.72$13.72$13.72
Upside/Downside-100.00%-100.00%133.24%

In the current month, the average price target of Day One Biopharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Day One Biopharmaceuticals's last price of $13.72. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024H.C. WainwrightBuyBuyHold
Oct 23, 2024Piper SandlerOverweightOverweightHold
Jul 08, 2024Piper SandlerOverweightOverweightHold
Jun 03, 2024Piper SandlerOverweightOverweightHold
May 07, 2024H.C. WainwrightBuyBuyHold
Apr 24, 2024Cowen & Co.BuyBuyHold
Jan 08, 2023Piper SandlerOverweightOverweightHold
Dec 14, 2022NeedhamBuyInitialise
Dec 05, 2022Goldman SachsBuyInitialise
Jun 20, 2022Piper SandlerOverweightOverweightHold
Row per page
Go to

Day One Biopharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave DAWN a "Buy" rating, the same as its previous rate.

Day One Biopharmaceuticals Financial Forecast

Day One Biopharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast$20.07M$20.07M$20.07M$20.07M$52.86M$46.15M$39.01M$32.44M$27.18M$28.48M$1.03M
High Forecast$21.55M$21.55M$21.55M$21.55M$56.76M$49.55M$41.88M$33.28M$28.73M$30.58M$1.03M
Low Forecast$18.57M$18.57M$18.57M$18.57M$48.91M$42.69M$36.09M$31.67M$24.60M$26.35M$1.03M
# Analysts22221114733
Surprise %-----------

Day One Biopharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DAWN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Day One Biopharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts22221114733
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict DAWN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Day One Biopharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Day One Biopharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts22221114733
Net Income-----------
Avg Forecast$-37.91M$-36.54M$-33.77M$-32.39M$-14.06M$-20.36M$-24.96M$-30.78M$-44.29M$-30.59M$-72.78M
High Forecast$-34.22M$-32.99M$-30.48M$-29.24M$-12.69M$-18.38M$-22.53M$-27.89M$-31.00M$-27.61M$-65.70M
Low Forecast$-41.54M$-40.04M$-37.00M$-35.50M$-15.40M$-22.31M$-27.35M$-33.66M$-102.75M$-33.52M$-79.76M
Surprise %-----------

Day One Biopharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DAWN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Day One Biopharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts22221114733
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Day One Biopharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DAWN last annual SG&A of $NaN (undefined).

Day One Biopharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts22221114733
EPS-----------
Avg Forecast$-0.39$-0.38$-0.35$-0.33$-0.14$-0.21$-0.26$-0.32$-0.46$-0.32$-0.75
High Forecast$-0.35$-0.34$-0.31$-0.30$-0.13$-0.19$-0.23$-0.29$-0.32$-0.28$-0.68
Low Forecast$-0.43$-0.41$-0.38$-0.37$-0.16$-0.23$-0.28$-0.35$-1.06$-0.35$-0.82
Surprise %-----------

According to undefined Wall Street analysts, Day One Biopharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DAWN previous annual EPS of $NaN (undefined).

Day One Biopharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals--979.41%Buy
INZYInozyme Pharma--422.06%Buy
PDSBPDS Bio--330.62%Buy
ABOSAcumen Pharmaceuticals--195.36%Buy
DAWNDay One Biopharmaceuticals--182.80%Buy
TERNTerns Pharmaceuticals--146.11%Buy
MREOMereo BioPharma Group--81.45%Buy
HOOKHOOKIPA Pharma--39.53%Buy

DAWN Forecast FAQ

Is Day One Biopharmaceuticals a good buy?

Yes, according to 5 Wall Street analysts, Day One Biopharmaceuticals (DAWN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of DAWN's total ratings.

What is DAWN's price target?

Day One Biopharmaceuticals (DAWN) average price target is $38.8 with a range of $24 to $45, implying a 182.80% from its last price of $13.72. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Day One Biopharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for DAWN stock, the company can go up by 182.80% (from the last price of $13.72 to the average price target of $38.8), up by 227.99% based on the highest stock price target, and up by 74.93% based on the lowest stock price target.

Can Day One Biopharmaceuticals stock reach $20?

DAWN's average twelve months analyst stock price target of $38.8 supports the claim that Day One Biopharmaceuticals can reach $20 in the near future.

What are Day One Biopharmaceuticals's analysts' financial forecasts?

Day One Biopharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $170.46M (high $181.47M, low $159.35M), average EBITDA is $0 (high $0, low $0), average net income is $-90.152M (high $-81.487M, low $-98.727M), average SG&A $0 (high $0, low $0), and average EPS is $-0.93 (high $-0.841, low $-1.018). DAWN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $80.28M (high $86.2M, low $74.27M), average EBITDA is $0 (high $0, low $0), average net income is $-141M (high $-127M, low $-154M), average SG&A $0 (high $0, low $0), and average EPS is $-1.451 (high $-1.309, low $-1.59).